中国现代医学杂志2025，Vol.35Issue(9)：7-12,6.DOI:10.3969/j.issn.1005-8982.2025.09.002
SLCO1B1和ApoE基因多态性对氯吡格雷治疗的超高危动脉粥样硬化性心血管疾病患者的影响
Impact of SLCO1B1 and ApoE gene polymorphisms on clopidogrel response in the very high-risk atherosclerotic cardiovascular disease patients
摘要
Abstract
Objective To investigate the influence of organic anion transporting polypeptide 1B1(OATP1B1,encoded by SLCO1B1)and apolipoprotein E(ApoE)gene polymorphisms on clopidogrel response in very high-risk atherosclerotic cardiovascular disease(ASCVD)patients.Methods We enrolled 183 very high-risk ASCVD patients treated with clopidogrel at our hospital from January 2023 to January 2024.Patients were stratified into resistant(n=51)and sensitive(n=132)groups based on clopidogrel response.SLCO1B1 and ApoE genotypes were determined,and their associations with clinical parameters were analyzed.Results The clopidogrel resistance rate was 27.87%(51/183).The resistant group showed significantly higher cholesterol levels(P<0.05),leukocyte counts(P<0.05),and diabetes prevalence(P<0.05)compared to the sensitive group.Genetic analysis revealed higher frequencies of SLCO1B1 1a/1b and 1b/1b genotypes in resistant patients(both P<0.05);Lowered 15 and increased 1b allele frequencies in resistant group(both P<0.05);Greater prevalence of ApoE e3/e4 and e4/e4 genotypes in resistant patients(both P<0.05);Higher e4 allele frequency in resistant group(P<0.05).Conclusion Both SLCO1B1 and ApoE polymorphisms significantly associate with clopidogrel resistance in ASCVD patients,suggesting potential pharmacogenetic markers for antiplatelet therapy optimization.关键词
动脉粥样硬化性心血管疾病/有机阴离子转运多肽1B1/载脂蛋白E/氯吡格雷Key words
atherosclerotic cardiovascular disease/organic anion transporting polypeptide 1B1/apolipoprotein E/clopidogrel分类
医药卫生引用本文复制引用
黄玉斌,张树江,王久凯,王宇飞..SLCO1B1和ApoE基因多态性对氯吡格雷治疗的超高危动脉粥样硬化性心血管疾病患者的影响[J].中国现代医学杂志,2025,35(9):7-12,6.基金项目
黑龙江省卫生健康委科研课题(No:20230303010159) （No:20230303010159）
中国高校产学研创新基金(No:2024GR031) （No:2024GR031）
